Clinical trials: Adjuvant Treatment
Sarcoma, Gastrointestinal Stromal Tumors
Adjuvant Imatinib in High-risk Gastrointestinal Stromal Tumor (GIST) With C-kit Mutation
The presence of c-kit mutation is an independent poor prognostic factor for relapse in addition to large size (> 5 cm) and high mitotic rate (> 5/50 high power field [HPF]) in localized gastrointestinal stromal tumor (GIST)…
- Trial name
- NCT00278876
- Testing
- Imatinib mesylate (Glivec)
- Where
- 4 sites in South Korea
- Volunteers
- 47 people
- Sponsor
- Asan Medical Center
Gastrointestinal Stromal Tumor
Imatinib Mesylate in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed By Surgery
This randomized phase III trial is studying imatinib mesylate to see how well it works compared to placebo in treating patients with primary gastrointestinal stromal tumor that has been completely removed by surgery.
- Trial name
- NCT00041197
- Testing
- imatinib mesylate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 732 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Adenocarcinoma, Stage IIIB Prostate Cancer American Joint Committee on Cancer (AJCC) v8
Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy
This phase II trial investigates the effect of extremely hypofractionated intensity modulated stereotactic body radiotherapy in treating patients with prostate cancer that has rising prostate specific antigen (PSA) after radical…
- Conditions
- Prostate Adenocarcinoma, Stage IIIB Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage IIIC Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
- Trial name
- EXCALIBUR (NCT04915508)
- Testing
- Hormone Therapy, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 165 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Rheumatoid Arthritis
Effect of Roflumilast and Desloratadine as Add-On Therapy in Patients With Rheumatoid Arthritis
Rheumatoid arthritis is a chronic inflammatory disease that causes joint pain, swelling, and disability. Although standard disease-modifying antirheumatic drugs (DMARDs) are effective for many patients, some individuals continue…
- Trial name
- NCT07566351
- Testing
- Roflumilast, Desloratadine
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- Horus University
Basal Cell Carcinoma of the Skin, Recurrent Skin Cancer
Vismodegib in Treating Patients With Basal Cell Carcinoma (BCC)
The purpose of this study is to learn about the effect of vismodegib on sporadic basal cell carcinoma (BCCs) prior to surgical removal.
- Trial name
- NCT01631331
- Testing
- vismodegib, Mohs surgery
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Stanford University
Breast Cancer
Assessment of Endometrial Changes in Postmenopausal Women With Breast Cancer in Adjuvant Treatment With Anastrozole
To investigate the global incidence of the endometrial changes in postmenopausal women receiving Anastrozole for the adjuvant treatment of hormone receptors positive breast cancer.
- Trial name
- NCT00623519
- Where
- 12 sites in Spain
- Volunteers
- 165 people
- Sponsor
- AstraZeneca
Breast Cancer
Clodronate With or Without Chemotherapy and/or Hormonal Therapy in Treating Women With Stage I or Stage II Breast Cancer
RATIONALE: Clodronate may be effective in preventing the spread of cancer to the bones and other parts of the body. It is not yet known whether clodronate is more effective alone or combined with chemotherapy and /or hormonal…
- Trial name
- NCT00009945
- Testing
- clodronate
- Where
- 17 sites in United States
- Volunteers
- 3,323 people
- Sponsor
- NSABP Foundation Inc
Peripheral Neuropathy in Breast Cancer Patient
Nutraceuticals Versus Usual Care in the Prevention or Reduction of CIPN in Patients Treated With Docetaxel as Neoadjuvant/Adjuvant Breast Cancer Therapy
The trial will utilize Nutraceuticals (Vitamin D 2000IU oral once daily, Vitamin B6 100 mg oral once daily, Vitamin B12 100 mcg oral once daily, Omega-3 Fatty Acids 900 mg oral three times a day) in patients treated with…
- Trial name
- CIPN (NCT02795572)
- Testing
- Vitamin D, Vitamin B6, Vitamin B12
- Where
- Canada
- Volunteers
- 13 people
- Sponsor
- AHS Cancer Control Alberta
NSCLC, Lung Cancer
IDO Peptid Vaccination for Stage III-IV Non Small-cell Lung Cancer Patients.
Title: IDO peptid vaccination in combination with immune stimulating agent Aldara and the adjuvant Montanide, for treatment of patients with locally advanced or metastatic non small-cell lung cancer. A first-in-man phase I trial.
- Trial name
- IDOvaccine (NCT01219348)
- Testing
- IDO peptide vaccination
- Where
- 2 sites in Denmark
- Volunteers
- 14 people
- Sponsor
- Inge Marie Svane
Gastric Cancer
A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric Cancer
This is a two-arm, randomized, double-blinded, multicenter phase III clinical study to evaluate the efficacy of HLX10 combined with chemotherapy versus placebo combined with chemotherapy for neoadjuvant/adjuvant treatment of…
- Trial name
- NCT04139135
- Testing
- HLX10
- Where
- 15 sites in China
- Volunteers
- 642 people
- Sponsor
- Shanghai Henlius Biotech
Sarcoma
Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST)
In this study, patients who have been diagnosed with gastrointestinal stromal tumor (GIST) will be randomly allocated in a 1:1 ratio to receive imatinib (Gleevec) either for 12 or for 36 months following surgery.
- Trial name
- NCT00116935
- Testing
- imatinib mesylate, imatinib
- Where
- Sweden
- Volunteers
- 400 people
- Sponsor
- Scandinavian Sarcoma Group
Solid Tumor
An Exploratory Study of Personalized Cancer Vaccine in Adjuvant Therapy of Solid Tumors
The purpose of this study is to evaluate the safety and tolerability of ABO2109 in combination with toripalimab, and to evaluate the immunogenicity, pharmacokinetics, pharmacodynamics, as well as biomarker characteristics of the…
- Trial name
- NCT07680582
- Testing
- ABO2109 Injection, Toripalimab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Ruijin Hospital
Biliary Tract Carcinoma
Irinotecan Liposomes +5-FU/LV Versus Capecitabine in Patients of Recurrence After Resection of Resectable BTC
Irinotecan liposome combined with 5-FU/LV has shown good efficacy and has certain advantages in reducing the adverse reactions of conventional chemotherapy drugs.
- Trial name
- NICRRBTC (NCT06699459)
- Testing
- Irinotecan Liposome, Capecitabine
- Where
- 6 sites in China
- Volunteers
- 76 people
- Sponsor
- Sir Run Run Shaw Hospital
Non-small Cell Lung Carcinoma
Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection
This is a multicenter, randomized, open label, phase III study.
- Trial name
- APEX (NCT04762459)
- Testing
- Almonertinib, Pemetrexed, Cisplatin
- Where
- 34 sites in China
- Volunteers
- 606 people
- Sponsor
- Chinese Academy of Medical Sciences
Pneumonitis, Immune-related Adverse Event
Inhaled Budesonide for REcurrence Prevention and Adjuvant THerapy in Checkpoint Inhibitor Pneumonitis
The introduction of immune checkpoint inhibitors (immunotherapy) that stimulate our immune system to recognize and attack cancer cells has been one of the most exciting advances in oncology over the last decade.
- Trial name
- NCT06860542
- Testing
- Arm 2- Budesonide (Pulmicort® Turbuhaler®) + Usual care, Arm 1- Usual care
- Where
- Canada
- Volunteers
- 94 people
- Sponsor
- AHS Cancer Control Alberta
Mucosal Melanoma
Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma
In many cancers, early stage diagnosis and early treatment offers the best chance of a prolonged recurrence free- and overall survival.
- Trial name
- Neo PeLeMM (NCT05545969)
- Testing
- Pembrolizumab, Lenvatinib
- Where
- Australia
- Sponsor
- Melanoma Institute Australia
Breast Cancer
Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways after surgery may kill more tumor cells.
- Trial name
- NCT00024102
- Testing
- Standard Treatment, capecitabine
- Where
- 334 sites in United States, Canada and 1 more
- Volunteers
- 633 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer
Study of Adriamycin Plus Cyclophosphamide Followed by Abraxane as Adjuvant Therapy for Patients With Breast Cancer
In this trial, the safety of combination treatment of Adriamycin plus cyclophosphamide followed by Abraxane as adjuvant therapy will be evaluated in patients with limited stage breast cancer.
- Trial name
- NCT00107094
- Testing
- Abraxane
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Celgene Corporation
HIV Infections
Effectiveness of Adding Remune to Your Current Anti-HIV Drug Combination
The purpose of this study is to see if giving a vaccine (Remune) is effective in HIV-positive patients who are also taking anti-HIV therapy.
- Trial name
- NCT00006153
- Testing
- HIV-1 Immunogen
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Musculoskeletal Pain, Breast Cancer
Phase 3 Study Randomized Evaluating the Efficacy of Auriculotherapy in Patients With Musculoskeletal Pain by Aromatase Inhibitors
Auriculotherapy is a complementary medicine, with few side effects, without contraindication, inexpensive and not very restrictive.Its efficacy has been found in several tests especially for the treatment of intraoperative pain.
- Trial name
- TRIPLE-A (NCT03096041)
- Testing
- Auriculotherapy for analgesic use
- Where
- 7 sites in France
- Volunteers
- 197 people
- Sponsor
- Centre Francois Baclesse
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.